PFAS expansion PACE Analytical Services is actively expanding its analytical capabilities, including a new ultrashort-chain PFAS testing method, signaling a focus on emerging contaminants and advanced analytical services that can be cross-sold to industries facing stricter regulatory scrutiny.

Life sciences growth The Life Sciences division has been expanding through acquisitions and new CDMO/CRO capabilities, including two life sciences laboratories and partnerships with drug developers, creating opportunities to upsell end-to-end pharmaceutical testing, formulation, manufacturing, and stability services.

Strategic partnerships Recent collaborations with Aspire Biolabs indicate Pace is positioned as a trusted testing and development partner for drug-excipient compatibility and formulation work, suggesting opportunities to co-create services with pharmaceutical and biotech clients.

Regulatory & safety focus Awards for regulatory-compliant testing (respirable crystalline silica) and a nationwide network emphasize Pace’s ability to support compliance-driven clients across air, water, soil, and occupational health, enabling cross-sell to industrials, construction, and environmental health programs.

Leadership and scale Recent executive appointments and a multi-billion revenue scale position Pace as a mature, resourceful partner capable of handling large-scale projects, enabling enterprise-grade collaboration prospects with government agencies, large manufacturers, and consulting firms seeking reliable laboratory data and services.